Report Detail

Pharma & Healthcare Global Meningococcal Group B Vaccine Market Insights, Forecast to 2025

  • RnM2652482
  • |
  • 17 April, 2019
  • |
  • Global
  • |
  • 113 pages
  • |
  • QYResearch
  • |
  • Pharma & Healthcare

Global Meningococcal Group B Vaccine Market Insights, Forecast to 2025

Table of Contents

    1 Study Coverage

    • 1.1 Meningococcal Group B Vaccine Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Meningococcal Group B Vaccine Market Size Growth Rate by Product
      • 1.4.2 Type 1
      • 1.4.3 Type 2
    • 1.5 Market by End User
      • 1.5.1 Global Meningococcal Group B Vaccine Market Size Growth Rate by End User
      • 1.5.2 Public
      • 1.5.3 Private
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Meningococcal Group B Vaccine Market Size
      • 2.1.1 Global Meningococcal Group B Vaccine Revenue 2014-2025
      • 2.1.2 Global Meningococcal Group B Vaccine Sales 2014-2025
    • 2.2 Meningococcal Group B Vaccine Growth Rate by Regions
      • 2.2.1 Global Meningococcal Group B Vaccine Sales by Regions
      • 2.2.2 Global Meningococcal Group B Vaccine Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Meningococcal Group B Vaccine Sales by Manufacturers
      • 3.1.1 Meningococcal Group B Vaccine Sales by Manufacturers
      • 3.1.2 Meningococcal Group B Vaccine Sales Market Share by Manufacturers
      • 3.1.3 Global Meningococcal Group B Vaccine Market Concentration Ratio (CR5 and HHI)
    • 3.2 Meningococcal Group B Vaccine Revenue by Manufacturers
      • 3.2.1 Meningococcal Group B Vaccine Revenue by Manufacturers (2014-2019)
      • 3.2.2 Meningococcal Group B Vaccine Revenue Share by Manufacturers (2014-2019)
    • 3.3 Meningococcal Group B Vaccine Price by Manufacturers
    • 3.4 Meningococcal Group B Vaccine Manufacturing Base Distribution, Product Types
      • 3.4.1 Meningococcal Group B Vaccine Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Meningococcal Group B Vaccine Product Type
      • 3.4.3 Date of International Manufacturers Enter into Meningococcal Group B Vaccine Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global Meningococcal Group B Vaccine Sales by Product
    • 4.2 Global Meningococcal Group B Vaccine Revenue by Product
    • 4.3 Meningococcal Group B Vaccine Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global Meningococcal Group B Vaccine Breakdown Data by End User

    6 North America

    • 6.1 North America Meningococcal Group B Vaccine by Countries
      • 6.1.1 North America Meningococcal Group B Vaccine Sales by Countries
      • 6.1.2 North America Meningococcal Group B Vaccine Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Meningococcal Group B Vaccine by Product
    • 6.3 North America Meningococcal Group B Vaccine by End User

    7 Europe

    • 7.1 Europe Meningococcal Group B Vaccine by Countries
      • 7.1.1 Europe Meningococcal Group B Vaccine Sales by Countries
      • 7.1.2 Europe Meningococcal Group B Vaccine Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Meningococcal Group B Vaccine by Product
    • 7.3 Europe Meningococcal Group B Vaccine by End User

    8 Asia Pacific

    • 8.1 Asia Pacific Meningococcal Group B Vaccine by Countries
      • 8.1.1 Asia Pacific Meningococcal Group B Vaccine Sales by Countries
      • 8.1.2 Asia Pacific Meningococcal Group B Vaccine Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific Meningococcal Group B Vaccine by Product
    • 8.3 Asia Pacific Meningococcal Group B Vaccine by End User

    9 Central & South America

    • 9.1 Central & South America Meningococcal Group B Vaccine by Countries
      • 9.1.1 Central & South America Meningococcal Group B Vaccine Sales by Countries
      • 9.1.2 Central & South America Meningococcal Group B Vaccine Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America Meningococcal Group B Vaccine by Product
    • 9.3 Central & South America Meningococcal Group B Vaccine by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa Meningococcal Group B Vaccine by Countries
      • 10.1.1 Middle East and Africa Meningococcal Group B Vaccine Sales by Countries
      • 10.1.2 Middle East and Africa Meningococcal Group B Vaccine Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Meningococcal Group B Vaccine by Product
    • 10.3 Middle East and Africa Meningococcal Group B Vaccine by End User

    11 Company Profiles

    • 11.1 GSK
      • 11.1.1 GSK Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 GSK Meningococcal Group B Vaccine Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 GSK Meningococcal Group B Vaccine Products Offered
      • 11.1.5 GSK Recent Development
    • 11.2 Pfizer
      • 11.2.1 Pfizer Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 Pfizer Meningococcal Group B Vaccine Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 Pfizer Meningococcal Group B Vaccine Products Offered
      • 11.2.5 Pfizer Recent Development

    12 Future Forecast

    • 12.1 Meningococcal Group B Vaccine Market Forecast by Regions
      • 12.1.1 Global Meningococcal Group B Vaccine Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Meningococcal Group B Vaccine Revenue Forecast by Regions 2019-2025
    • 12.2 Meningococcal Group B Vaccine Market Forecast by Product
      • 12.2.1 Global Meningococcal Group B Vaccine Sales Forecast by Product 2019-2025
      • 12.2.2 Global Meningococcal Group B Vaccine Revenue Forecast by Product 2019-2025
    • 12.3 Meningococcal Group B Vaccine Market Forecast by End User
    • 12.4 North America Meningococcal Group B Vaccine Forecast
    • 12.5 Europe Meningococcal Group B Vaccine Forecast
    • 12.6 Asia Pacific Meningococcal Group B Vaccine Forecast
    • 12.7 Central & South America Meningococcal Group B Vaccine Forecast
    • 12.8 Middle East and Africa Meningococcal Group B Vaccine Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Meningococcal Group B Vaccine Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      The global Meningococcal Group B Vaccine market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Meningococcal Group B Vaccine market based on company, product type, end user and key regions.

      This report studies the global market size of Meningococcal Group B Vaccine in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Meningococcal Group B Vaccine in these regions.
      This research report categorizes the global Meningococcal Group B Vaccine market by top players/brands, region, type and end user. This report also studies the global Meningococcal Group B Vaccine market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      GSK
      Pfizer

      Market size by Product
      Type 1
      Type 2
      Market size by End User
      Public
      Private

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global Meningococcal Group B Vaccine market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of Meningococcal Group B Vaccine market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global Meningococcal Group B Vaccine companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of Meningococcal Group B Vaccine submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of Meningococcal Group B Vaccine are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Meningococcal Group B Vaccine market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.


      Summary:
      Get latest Market Research Reports on Meningococcal Group B Vaccine . Industry analysis & Market Report on Meningococcal Group B Vaccine is a syndicated market report, published as Global Meningococcal Group B Vaccine Market Insights, Forecast to 2025. It is complete Research Study and Industry Analysis of Meningococcal Group B Vaccine market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.


      REPORT YOU MIGHT BE INTERESTED

      Purchase this Report

      $3,900.00
      $5,850.00
      $7,800.00
      3,072.82
      4,609.23
      6,145.64
      3,443.93
      5,165.90
      6,887.87
      419,101.80
      628,652.70
      838,203.60
      271,221.60
      406,832.40
      542,443.20
      Credit card Logo

      Related Reports


      Reason to Buy

      Request for Sample of this report